Arena Pharmaceuticals, Inc. (ARNA)
(Delayed Data from NSDQ)
$47.60 USD
+1.62 (3.52%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.68 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.60 USD
+1.62 (3.52%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.68 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.
What's in Store for Puma (PBYI) this Earnings Season?
by Zacks Equity Research
Recent approval of Puma's (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same.
What's in Store for Arena (ARNA) this Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.
Mylan (MYL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Mylan N.V. (MYL) is expected to focus on the performance of EpiPen and progress with the biosimilars pipeline during its second-quarter results.
Can CVS Health (CVS) Pull a Surprise this Earnings Season?
by Zacks Equity Research
CVS Health (CVS) is poised to gain on strong Pharmacy Services numbers that benefited from the upside in Specialty Pharmacy in Q2.
What's in the Cards for Celldex (CLDX) this Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.
Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
Can Ligand (LGND) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.
GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?
by Zacks Equity Research
Investors will likely be looking at GW Pharmaceuticals' (GWPH) progress with its anti-epileptic pipeline candidate, Epidiolex in its fiscal third-quarter results.
Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on Mallinckrodt plc's (MNK) progress with its strategic acquisitions and pipeline updates.
What's in the Cards for Adverum (ADVM) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.
What's in the Cards for Merrimack (MACK) in Q2 Earnings?
by Zacks Equity Research
Sales of Merrimack Pharmaceuticals, Inc???s (MACK) only approved product, Onivyde to Ipsen is expected to bring in $450 million this quarter.
AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study
by Zacks Equity Research
AstraZeneca PLC (AZN) reported second-quarter 2017 core earnings of 87 cents per ADS, which beat the Zacks Consensus Estimate of 41 cents. Failure in lung cancer study on Imfinzi however pulled the stock down.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.
Top Ranked Momentum Stocks to Buy for July 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 24th:
Arena Announces Secondary Stock Worth $150M (revised)
by Zacks Equity Research
Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.
Why Arena Pharmaceuticals (ARNA) Could Be Positioned for a Surge
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Top Ranked Momentum Stocks to Buy for July 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 14th:
Company News for July 12, 2017
by Zacks Equity Research
Companies in the News are: FOLD,SLP,ARNA,EVGN,MON
Arena Announces Secondary Stock Offering of 150M Shares
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.
Here's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today
by Madeleine Johnson
On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs.
Arena's Ralinepag Positive in Phase II PAH Study, Shares Up
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.
Are Options Traders Betting on a Big Move in Arena Pharmaceuticals (ARNA) Stock?
by Zacks Equity Research
Investors in Arena Pharmaceuticals, Inc. (ARNA) need to pay close attention to the stock based on moves in the options market lately.
Arena Ends Study on Extended Release Formulation of PAH Drug
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.